ABSTRACT
INTRODUCTION This study examined the impact of apolipoprotein ɛ4 (APOEɛ4) allele frequency and sex on the phenotype of Alzheimer’s disease (AD).
METHODS The baseline characteristics, CSF, and neuroimaging biomarkers, and cognition scores collected from 45 patients aged 50-74 years with confirmed early AD from clinical trial NCT03186989 were evaluated in a post-hoc study.
RESULTS A phenotypic spectrum was observed from a predominant amyloid and limbic-amnestic phenotype in male APOEɛ4 homozygotes to a predominantly tau, limbic-sparing, and multidomain cognitive impairment phenotype in female APOEɛ4 noncarriers. Amyloid pathology inversely correlated with tau pathophysiology, glial activation, and synaptic injury, with the strongest correlations observed in male APOEɛ4 carriers. Tau pathophysiology was correlated with glial activation, synaptic injury, and neuroaxonal damage, with the strongest correlation observed in female APOEɛ4 noncarriers.
DISCUSSION Glial activation is influenced by apoE isoform and sex, which explains much of the phenotypic heterogeneity in early AD below age 75 years.
HIGHLIGHTS
APOEɛ4 homozygotes displayed a predominantly amyloid and limbic-amnestic phenotype.
Female APOEɛ4 noncarriers displayed a predominantly tau, limbic-sparing, and multidomain cognitive impairment phenotype.
In male APOEɛ4 carriers, amyloid pathology was inversely correlated with tau pathophysiology, synaptic injury, and glial activation
Females displayed a non-APOEɛ4 allele frequency-dependent increase in glial activation and synaptic injury
In female APOEɛ4 noncarriers, tau pathophysiology was strongly correlated with glial activation, synaptic injury, and neuroaxonal damage
Systematic review The impact of APOEɛ4 alleles and sex on phenotypic features was examined in 45 patients, aged 50-74 years, with early AD.
Interpretation Findings were consistent with prior reports and suggest that glial activation, influenced by apoE isoform and sex, explains much of the phenotypic heterogeneity in early AD below age 75 years. Lower glial activation in APOEɛ4 homozygotes associated with the highest levels of amyloid and the lowest levels of tau pathology, and a limbic-amnestic phenotype, suggesting degeneration of basal forebrain cholinergic neurons. Higher glial activation in female APOEɛ4 noncarriers was associated with the highest tau pathology and synaptic injury, the lowest amyloid pathology, greater ventricular expansion, and multi-domain cognitive deficits.
Future directions This work defined a combined sex, genotype, and age framework that delineates multiple pathways to end-stage AD. Confirmation is required, followed by optimization of therapeutic approaches to amyloid, tau, and glial activation pathologies along the disease stage continuum.
Competing Interest Statement
RML and DL are Employees of, and holders of stock/stock options in, Ionis Pharmaceuticals Inc. TDS has no conflicts of interest.
Funding Statement
This study was funded by Biogen and designed and operationalized by Ionis
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the following institutions: Ethikkommission der Universitat Ulm, 412/16; Ethik-Kommission der Ruhr-Universitat Bochum, 16-5929:London-Central Research Ethics Committee Manchester HRA Centre, 2017-3206; MUHC Neuroscience Research Ethics Board, 2017-3206; National Committee on Medical Research Ethics, 73/06.00.01/2017; Ethikkommission der Sachsischen Landesarztekammer, EK-AMG-MCB-155/16-1; Central Committee on Research Involving Human Subjects, NL60032.000.16; Regionala etikprovningsnamnden i Stockholm Karolinska Institutet i Solna, 2017/300-31; Ethikkommission an der Medizinischen Fakultat der Rheinischen, 035/18-AMG
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Declaration of Interest: RML and DL are Employees of, and holders of stock/stock options in, Ionis Pharmaceuticals Inc. TDS has no conflicts of interest.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
